EGFR and non-small cell lung carcinoma: Amivantamab, a fully human bispecific antibody (BsAb) that targets both EGFR and cMET, received FDA approval in May 2021 for the treatment of advanced or metastatic NSCLC with EGFR Ex20ins mutations (5, 16, 17).